Metastatic Breast Cancer - Pipeline Review, H2 Pharmaceutical 2016
"Metastatic
Breast Cancer - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016,
provides an overview of the Metastatic Breast Cancer (Oncology)
pipeline landscape.
Metastatic
breast cancer (also called Stage IV or Advanced) is a stage of breast
cancer in which cancer cells break away from the tumor in the breast,
spread to other parts of the body and keep growing. Symptoms of
metastatic breast cancer includes severe, progressive pain, and, less
commonly, pathological fracture, erythema over the affected bone,
swelling, jaundice, elevated liver enzymes, abdominal pain, loss of
appetite, nausea, and vomiting. Other symptoms include fatigue,
malaise and weight loss. Treatment includes hormone therapy,
chemotherapy, radiation therapy and surgery.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Metastatic Breast Cancer - Pipeline Review, H2 2016, provides
comprehensive information on the therapeutics under development for
Metastatic Breast Cancer (Oncology), complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Metastatic Breast Cancer (Oncology) pipeline guide also reviews of
key players involved in therapeutic development for Metastatic Breast
Cancer and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical, Discovery and Unknown stages are 8, 33, 81, 52, 2, 52, 7
and 3 respectively. Similarly, the Universities portfolio in Phase
II, Phase I, Preclinical and Discovery stages comprises 4, 7, 7 and 1
molecules, respectively.Metastatic Breast Cancer.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Metastatic Breast Cancer (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Metastatic
Breast Cancer (Oncology) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Metastatic
Breast Cancer (Oncology) therapeutics and enlists all their major and
minor projects.
-
The pipeline guide evaluates Metastatic Breast Cancer (Oncology)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Metastatic Breast Cancer (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Metastatic Breast Cancer (Oncology) pipeline depth and focus of
Indication therapeutics.
Comments
Post a Comment